RAPT Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced that President and CEO Brian Wong will present at the Stifel 2020 Virtual Healthcare Conference on November 18, 2020, at 4:00 p.m. ET. The event will be accessible via a live webcast on the RAPT Therapeutics website. The company focuses on developing oral small molecule therapies for unmet needs in oncology and inflammatory diseases. RAPT has advanced drug candidates FLX475 and RPT193, targeting CCR4, along with other developmental targets including HPK1 and GCN2.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present at the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, 2020 at 4:00 p.m. ET.
A live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations. Please connect to the website 10 minutes prior to the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.
About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets, including hematopoietic progenitor kinase 1 (HPK1) and general control nonderepressible 2 (GCN2), that are in the discovery stage of development.
RAPT Media Contact:
Angela Bitting
media@rapt.com
(925) 202-6211
RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com
FAQ
When will RAPT Therapeutics present at the Stifel 2020 Virtual Healthcare Conference?
Who will present for RAPT at the Stifel Healthcare Conference?
How can I access the presentation by RAPT Therapeutics?
What are the key drug candidates of RAPT Therapeutics?
What is the focus of RAPT Therapeutics?
